Hemodynamic Effects of Ketone Bodies in Patients With Pulmonary Hypertension
Гемодинамические эффекты кетоновых тел у пациентов с легочной гипертензией
2023-05-15
SCID: 54.1/psw9g8vy
Discuss with AI
3‑hydroxybutyrate (3‑OHB)cardiac outputchronic thromboembolic pulmonary hypertension (CTEPH)pulmonary arterial hypertension (PAH)pulmonary vascular resistance
Figures from the paper
Abstract (AI)
Background Pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) are debilitating diseases with a high mortality. Despite emerging treatments, pulmonary vascular resistance frequently remains elevated. However, the ketone body 3‐hydroxybutyrate (3‐OHB) may reduce pulmonary vascular resistance in these patients. Hence, the aim was to assess the hemodynamic effects of 3‐OHB in patients with PAH or CTEPH. Methods and Results We enrolled patients with PAH (n=10) or CTEPH (n=10) and residual pulmonary hypertension. They received 3‐OHB infusion and placebo (saline) for 2 hours in a randomized crossover study. Invasive hemodynamic and echocardiography measurements were performed. Furthermore, we investigated the effects of 3‐OHB on the right ventricle of isolated hearts and isolated pulmonary arteries from Sprague–Dawley rats. Ketone body infusion increased circulating 3‐OHB levels from 0.5±0.5 to 3.4±0.7 mmol/L ( P <0.001). Cardiac output improved by 1.2±0.1 L/min (27±3%, P <0.001), and right ventricular annular systolic velocity increased by 1.4±0.4 cm/s (13±4%, P =0.002). Pulmonary vascular resistance decreased by 1.3±0.3 Wood units (18%±4%, P <0.001) with no significant difference in response between patients with PAH and CTEPH. In the rat studies, 3‐OHB administration was associated with decreased pulmonary arterial tension compared with saline administration (maximal relative tension difference: 12±2%, P <0.001) and had no effect on right ventricular systolic pressures ( P =0.63), whereas pressures rose at a slower pace (dP/dtmax, P =0.02). Conclusions In patients with PAH or CTEPH, ketone body infusion improves cardiac output and decreases pulmonary vascular resistance. Experimental rat studies support that ketone bodies relax pulmonary arteries. Long‐term studies are warranted to assess the clinical role of hyperketonemia. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04615754.
Key Findings
1
3‐OHB infusion increased cardiac output by 1.2±0.1 L/min (27±3%, P<0.001) in patients with PAH or CTEPH.
2
In isolated rat hearts, 3‐OHB had no effect on right ventricular systolic pressures (P=0.63) but slowed the rate of pressure rise (dP/dtmax, P=0.02).
3
In isolated rat pulmonary arteries, 3‐OHB reduced maximal relative tension by 12±2% compared with saline (P<0.001), indicating pulmonary arterial relaxation.
4
Intravenous 3‐hydroxybutyrate (3‐OHB) infusion raised circulating 3‐OHB levels from 0.5±0.5 to 3.4±0.7 mmol/L (P<0.001).
5
Pulmonary vascular resistance decreased by 1.3±0.3 Wood units (18%±4%, P<0.001) with no significant difference between PAH and CTEPH patients.
6
Right ventricular annular systolic velocity increased by 1.4±0.4 cm/s (13±4%, P=0.002) during 3‐OHB infusion.
7
The study concludes ketone body infusion improves cardiac output and decreases pulmonary vascular resistance in PAH/CTEPH, supporting further long-term studies.
Research Object
Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) receiving 3‐hydroxybutyrate (3‑OHB) infusion
Research Subject
Hemodynamic effects of 3‑hydroxybutyrate infusion, specifically changes in pulmonary vascular resistance, cardiac output, right ventricular function, and pulmonary arterial tension
Publication Details
Publication Date
2023-05-15
Journal
Publisher
ISSN
Cited by
36
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest